Clarity Peptide Imaging services

Clarity’s Mission

 

At Clarity, our mission is to develop innovative radiopharmaceuticals that improve patient outcomes.

 

Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

Clarity’s platform technology allows peptides and antibodies to be radiolabeled for visualisation using PET imaging and therapy. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach by only treating those patients that are likely to respond to therapy and excluding those that won’t. This precision medicine approach is at the forefront of drug development.

Find out more
pharmaceutical development

Pharmaceutical Development

 

Clarity develops personalised medicine diagnostic imaging and therapeutic products. By using its proprietary technology, Clarity is developing next generation theranostic solutions for serious diseases, such as cancer, that are not well treated by current therapies.

 

Clarity Pharmaceuticals actively manages an in-house drug development program, with its first drug SARTATE™, an oncology theranostic (diagnostic and therapy), in clinical trials for meningioma and neuroendocrine tumours in adult patients. This new agent will also potentially allow better treatment of paediatric cancers and is in clinical trials for neuroblastoma. Clarity is in a number of negotiations to expand its program and tap into new markets that can be better served with our SAR Technology. As such, the prostate cancer market remains a key focus for the Company. Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment and has the potential to provide multiple benefits in comparison to current technologies. Clarity is also in early preclinical development with a small range of other therapies for a broad range of cancers.

Find out more